Integrum AB (publ) (INTEG-B.ST) Stock Analysis & Winston Score

Integrum AB is a Swedish medical device company that makes osseointegrated prosthetic limb systems. Its main product, the OPRA Implant System, is a titanium implant that attaches directly to the bone of an amputee, allowing a prosthetic limb to connect without a traditional socket. The company sells primarily to hospitals and specialist clinics, serving patients who have lost a limb and struggle with conventional socket-based prosthetics. Integrum earns revenue by selling implant hardware and related surgical components to healthcare providers, with procedures typically reimbursed through national health systems or private insurers. The company operates mainly in Europe, with growing activity in the United States following FDA clearance, and remains a small-cap business with a narrow but specialized focus. Its negative gross and operating margins reflect the high costs of a small commercial-stage medical device company, and the key challenge ahead is scaling U.S. market adoption and securing broader insurance reimbursement coverage to reach profitability.